Coated medicine loaded with limonin as well as preparation method and application of coated medicine

By wrapping limonein in exosomes and encapsulating it in the coated shell of enteric acrylic resin material, combining hydroxy acids, the anti-inflammatory drugs in the prior art cannot directly act on the intestine and limonein to the stomach. The problem of intestinal irritation has achieved targeted, efficient anti-inflammatory and tissue repair of intestinal inflammation.

CN118924697AActive Publication Date: 2024-11-12GUANGDONG GREENTECH LEMON INNOVATIONS CO LTD
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202411166925.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-23
Publication Date
2024-11-12
Estimated Expiration
2044-08-23

AI Technical Summary

Technical Problem

Existing anti-inflammatory drugs cannot directly act on the intestine, and limonogins are highly irritating to the gastrointestinal tract, leading to side effects, making it difficult to effectively treat intestinal inflammation.

Method used

Limonopherin is encapsulated in the exosome, and then wrapped in the coated shell of the enteric-coated acrylic resin material. Used in conjunction with hydroxy acids, and form the first and second exosomes by incubation, electro-rotation, extrusion or ultrasound methods. , achieve fixed-point release.

Benefits of technology

It achieves site-directed and effective anti-inflammatory properties of intestinal inflammation, avoids side effects, improves the intestinal environment through biological factors and carboxylic acids in exosomes, and promotes cell metabolism and tissue repair.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118924697A_ABST
    Figure CN118924697A_ABST
Patent Text Reader

Abstract

The invention discloses a limonin-loaded coated drug and a preparation method and application thereof.The coated drug comprises a coating shell and functional components located in the coating shell, and the functional components comprise a first exosome loaded with limonin and a second exosome loaded with hydroxy acid. According to the limonin-loaded coated drug provided by the invention, the limonin is firstly coated in the exosome and then coated in the coating shell, and meanwhile, the limonin is matched with the exosome and the carboxylic acid to be used at the same time, so that intestinal inflammation can be effectively relieved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of coated limonin, in particular to a coated medicine loaded with limonin and a preparation method and application thereof. Background Art

[0002] Currently, the treatment for intestinal inflammation is all carried out with conventional anti-inflammatory drugs. Conventional anti-inflammatory drugs cannot act directly on the intestinal tract, and after oral administration, anti-inflammatory drugs may be dissolved in the stomach or before reaching the intestine. Their efficacy acts at various locations in the digestive system and cannot be accurately located in the intestine to solve the problem of intestinal inflammation.

[0003] Limonin has multiple biological activities such as anti-tumor, insect repellent, antiviral, analgesic, anti-inflammatory, and hypnotic, and can be used as functional food additives, anti-cancer foods, pesticides, feed additives, etc. However, limonin may irritate the gastrointestinal tract and cause nausea, vomiting, diarrhea and other discomfort symptoms; therefore, when used as food or medicine, it may stimulate gastric acid secretion and cause side effects. Therefore, it is only used as a small amount of additives and cannot be taken directly as food or medicine. Summary of the invention

[0004] The present invention aims to solve one of the problems in the related art to at least a certain extent. To this end, the present invention aims to provide a coated drug loaded with limonin, which can effectively relieve intestinal inflammation by first encapsulating the limonin in exosomes and then in a coating shell, and using the exosomes and carboxylic acid at the same time.

[0005] A coated drug loaded with limonin comprises: a coating shell and an effective component located in the coating shell, wherein the effective component comprises a first exosome loaded with limonin and a second exosome loaded with a hydroxy acid.

[0006] Furthermore, the hydroxy acid comprises the following components in parts by weight: 35-45 parts of lactic acid, 30-40 parts of malic acid and 15-30 parts of citric acid.

[0007] Furthermore, the drug-encapsulated coating shell is made of polyacrylic acid resin material.

[0008] Furthermore, the coating shell of the coated drug is enteric-coated type I acrylic resin, and the dissolution pH of the coating shell is greater than 5.5.

[0009] Furthermore, the weight ratio of the first exosomes to the second exosomes is 70-80:20-30.

[0010] A method for preparing a coated drug loaded with limonin, comprising:

[0011] loading limonin into exosomes to form first exosomes;

[0012] loading hydroxy acids into exosomes to form second exosomes;

[0013] The first exosomes and the second exosomes are prepared into coated drugs through coating technology.

[0014] Furthermore, limonin is encapsulated into exosomes to form first exosomes by incubation, electroporation, extrusion, ultrasound or freeze-thaw method.

[0015] Furthermore, the hydroxy acid is encapsulated into exosomes to form second exosomes by incubation, electroporation, extrusion, ultrasound or freeze-thaw method.

[0016] Application of a coated drug loaded with limonin in the field of treating enteritis.

[0017] The above technical solution provided by the embodiment of the present application has the following advantages over the prior art: after the coated drug in the present application enters the human body, the outer coating shell is decomposed, so that the internal effective components are released, and the effective components include the first exosomes loaded with limonin and the second exosomes loaded with hydroxy acid. The exosomes contain cell-specific proteins, lipids and nucleic acids, which play a role in regulating cell status and function. At the same time, the exosomes also contain rich biological factors, which can promote cell metabolism, activate cell regeneration ability, and repair damaged tissues; when the exosomes are gradually dissolved, the limonin and carboxyl acid encapsulated therein are released. Under the coordinated action of the exosome biological factors, the carboxyl acid can improve the intestinal environment and alleviate intestinal problems caused by various reasons such as intestinal flora disorders and redox imbalance; limonin is used to reduce inflammation in the intestine after the environment is improved; in the present application, the coated drug can be released at a fixed point, and on the basis of the improvement of the exosome biological factors and carboxyl acids, limonin can achieve effective anti-inflammatory effects on the intestine, and has a fixed and efficient anti-inflammatory effect. BRIEF DESCRIPTION OF THE DRAWINGS

[0018] Figure 1 This is a schematic diagram of the results of the in vitro release test in Experimental Example 1. DETAILED DESCRIPTION

[0019] The following examples are used to illustrate the present invention, but are not intended to limit the scope of the present invention. Without departing from the spirit and essence of the present invention, modifications or substitutions made to the methods, steps or conditions of the present invention all belong to the scope of protection of the present invention. Unless otherwise specified, the experimental materials, reagents, instruments, etc. used in the examples of the present invention are all commercially available; unless otherwise specified, all technical means in the examples of the present invention are conventional means well known to those skilled in the art.

[0020] The present application provides a coated drug loaded with limonin, comprising: a coating shell and an effective component located in the coating shell, wherein the effective component comprises a first exosome loaded with limonin and a second exosome loaded with hydroxy acid; and the weight ratio of the first exosome to the second exosome is 70-80:20-30. Specifically, the hydroxy acid comprises the following components in parts by weight: 35-45 parts of lactic acid, 30-40 parts of malic acid and 15-30 parts of citric acid; carboxylic acid can improve the intestinal environment and alleviate intestinal problems caused by various reasons such as intestinal flora disorder and redox imbalance. Exosomes contain cell-specific proteins, lipids and nucleic acids, which play a role in regulating cell status and function. At the same time, exosomes also contain rich biological factors, which can promote cell metabolism, activate cell regeneration ability, and repair damaged tissues. Limonin is used to reduce inflammation in the intestine after the environment is improved, and the anti-inflammatory effect of limonin needs to be based on the biological activity of exosomes and the improvement of the intestinal environment by carboxylic acid.

[0021] In this application, exosomes are used as oral drugs, specifically milk exosomes. Milk exosomes are separated and purified from fresh milk, with a diameter of about 30 to 200 nm. They are rich in the same phospholipid bilayer membrane structure as the cell membrane, tightly wrapping cytokines, growth factors and other specific proteins, lipids, miRNA, DNA fragments, etc., which can quickly break through the cell biological membrane barrier, accurately identify and locate cell damage, etc. Milk exosomes have a unique microbubble category, which maintains the integrity of the nucleic acids and proteins contained in it while passing through the stomach and gastrointestinal tract, and can act locally or be transported to the circulatory system.

[0022] The coating shell of the coated drug described in the present application is a polyacrylic acid resin material, and the polyacrylic acid resin is used as a film coating material of the coated drug. By selecting different types of polyacrylic acid resins, it can be ensured that the coated drug is dissolved in different environments, thereby achieving the targeted and effective release of the functional components inside the coated drug.

[0023] Specifically, the coating shell of the coated drug is enteric-coated type I acrylic resin, and the dissolution pH of the coating shell is greater than 5.5. In the human digestive system, the pH of gastric juice is 2; the pH of small intestinal juice is 6.8; the pH of cecal juice is 7.5. When the coated drug is taken, it is first eroded by gastric juice and then enters the intestinal fluid environment. The enteric-coated type I acrylic resin will not be dissolved in the gastric acid environment, but will begin to dissolve when it reaches the intestine, so that the active ingredients inside the coated drug are released; thereby achieving targeted and effective drug release.

[0024] The present application provides a method for preparing a coated drug loaded with limonin, comprising:

[0025] S1: Limonin is loaded into exosomes to form the first exosomes.

[0026] Specifically, limonin is encapsulated into exosomes to form first exosomes by incubation or electroporation or extrusion or ultrasound or freeze-thaw method. For example, when encapsulation is performed by incubation method, the exosome suspension and the limonin solution are mixed and incubated at a certain temperature for a certain time. Subsequently, the above solution is placed in an ultrafiltration tube with a certain molecular weight cutoff, and ultrafiltration and washing are performed three times using a biocompatible medium to obtain the first exosome loaded with limonin. The concentration of the limonin solution is 15.6 μL / mL.

[0027] S2: Loading hydroxy acids into exosomes to form second exosomes.

[0028] Specifically, the hydroxy acid is encapsulated into the exosomes to form the second exosomes by incubation or electroporation or extrusion or ultrasound or freeze-thaw method. For example, when the electroporation method is used for encapsulation, the exosome suspension is mixed with the carboxylic acid solution and the electroporation solution, placed in an electroporator, and electroporated for a certain time under certain conditions. Subsequently, the above solution is placed in an ultrafiltration tube with a certain molecular weight cutoff, and ultrafiltration and washing are performed three times using a biocompatible medium to obtain the first exosomes loaded with the carboxylic acid.

[0029] S3: The first exosomes and the second exosomes are prepared into coated drugs through coating technology.

[0030] The application of a coated drug loaded with limonin provided in the present application can achieve the targeted release of the effective ingredients according to the selected exosome type and coating shell material type. When the coating shell of the coated drug is enteric-coated type I acrylic resin, since the dissolution pH of the coating shell is greater than 5.5, the coated drug is used in the technical field of enteritis treatment.

[0031] Example 1

[0032] The present embodiment provides a coated drug loaded with limonin, comprising: a coating shell and an effective component located in the coating shell, wherein the effective component comprises a first exosome loaded with limonin and a second exosome loaded with hydroxy acid; and the weight ratio of the first exosome to the second exosome is 80:20. Specifically, the hydroxy acid comprises the following components in parts by weight: 35 parts of lactic acid, 40 parts of malic acid and 25 parts of citric acid. In the present embodiment, the exosomes are specifically milk exosomes, and the coating shell of the coated drug is enteric-coated type I acrylic resin.

[0033] The present embodiment provides a method for preparing a coated drug loaded with limonin, comprising:

[0034] S1: Limonin is loaded into exosomes by an incubation method to form the first exosomes. The concentration of the limonin solution is 15.6 μL / mL.

[0035] S2: The hydroxy acid is loaded into the exosomes by electroporation to form a second exosome; the hydroxy acid includes the following components in parts by weight: 35 parts of lactic acid, 40 parts of malic acid and 25 parts of citric acid.

[0036] S3: Weigh the first exosome and the second exosome in a weight ratio of 80:20, and prepare them into coated drugs by coating technology. The coating shell of the coated drug is enteric-coated type I acrylic resin.

[0037] In this embodiment, the coated drug loaded with limonin is used in the treatment of enteritis.

[0038] Example 2

[0039] The present embodiment provides a coated drug loaded with limonin, comprising: a coating shell and an effective component located in the coating shell, wherein the effective component comprises a first exosome loaded with limonin and a second exosome loaded with hydroxy acid; and the weight ratio of the first exosome to the second exosome is 70:30. Specifically, the hydroxy acid comprises the following components in parts by weight: 45 parts of lactic acid, 30 parts of malic acid and 25 parts of citric acid. In the present embodiment, the exosomes are specifically milk exosomes, and the coating shell of the coated drug is enteric-coated type I acrylic resin.

[0040] The present embodiment provides a method for preparing a coated drug loaded with limonin, comprising:

[0041] S1: Limonin is loaded into exosomes by an incubation method to form the first exosomes. The concentration of the limonin solution is 15.6 μL / mL.

[0042] S2: The hydroxy acid is loaded into the exosomes by electroporation to form a second exosome; the hydroxy acid includes the following components in parts by weight: 45 parts of lactic acid, 30 parts of malic acid and 25 parts of citric acid.

[0043] S3: Weigh the first exosome and the second exosome in a weight ratio of 70:30, and prepare them into coated drugs by coating technology. The coating shell of the coated drug is enteric-coated type I acrylic resin.

[0044] In this embodiment, the coated drug loaded with limonin is used in the treatment of enteritis.

[0045] Example 3

[0046] The present embodiment provides a coated drug loaded with limonin, comprising: a coating shell and an effective component located in the coating shell, wherein the effective component comprises a first exosome loaded with limonin and a second exosome loaded with hydroxy acid; and the weight ratio of the first exosome to the second exosome is 76:24. Specifically, the hydroxy acid comprises the following components in parts by weight: 43 parts of lactic acid, 37 parts of malic acid and 20 parts of citric acid. In the present embodiment, the exosomes are specifically milk exosomes, and the coating shell of the coated drug is enteric-coated type I acrylic resin.

[0047] The present embodiment provides a method for preparing a coated drug loaded with limonin, comprising:

[0048] S1: Limonin is loaded into exosomes by an incubation method to form the first exosomes. The concentration of the limonin solution is 15.6 μL / mL.

[0049] S2: The hydroxy acid is loaded into the exosomes by electroporation to form a second exosome; the hydroxy acid includes the following components in parts by weight: 43 parts of lactic acid, 37 parts of malic acid and 20 parts of citric acid.

[0050] S3: Weigh the first exosome and the second exosome in a weight ratio of 76:24, and prepare them into coated drugs by coating technology. The coating shell of the coated drug is enteric-coated type I acrylic resin.

[0051] Comparative Example 1

[0052] The difference from Example 2 is that only the first exosomes are included, and the second exosomes are not included.

[0053] Experimental Example 1

[0054] In order to study whether the coated drugs can be released at a specific point in the intestine, the coated blank pills were used as the research objects. The absorbance values ​​were detected after incubation at different time points and in different intestinal fluids to reflect the release pattern.

[0055] Determination of in vitro release of encapsulated drugs

[0056] (1) The specific determination method is:

[0057] Weigh 100 mg of blank drug and add 200 μL of gastric juice, small intestinal juice and cecal juice in turn. The pH of gastric juice is 2; the pH of small intestinal juice is 6.8; the pH of cecal juice is 7.5. The mixture is incubated at 80 rpm and 37 °C. First, gastric juice is added to all blank drugs, and 3 tubes of mixture are taken out at 0.5h, 1h, 1.5h, and 2h respectively and stored at 4 °C; the gastric juice is aspirated from the remaining tubes, replaced with small intestinal juice and continued to be incubated, and 3 tubes of mixture are taken out at 3h, 4h, 5h, and 6h respectively and stored at 4 °C; the small intestinal juice is aspirated from the remaining tubes, replaced with cecal juice and continued to be incubated, and 3 tubes of mixture are taken out at 7h, 8h, 9h, 10h, 11h, and 12h respectively and stored at 4 °C. Then all samples are taken out from 4 °C, and 100 μL of supernatant is aspirated to detect OD600 in a multifunctional microplate reader.

[0058] (2) The results are as follows Figure 1 As shown. Figure 1 It can be seen that the in vitro release test shows that the release rate of blank pills in gastric juice and small intestinal juice is less than 10%, but it can be completely released in large intestinal juice.

[0059] Experimental Example 2

[0060] Evaluation of inflammation reduction efficacy (neutrophils)

[0061] 3dpf transgenic neutrophil green fluorescent MPX strain zebrafish were randomly selected in a multi-well plate, and 30 zebrafish were treated in each well (experimental group). The positive control group, normal control group, model control group, experimental group 1, test group 2, experimental group 3, and control group 1 were given water solution respectively. The normal control group was zebrafish without inflammation and was not treated in any way. Experimental group 1 was the solution after the coated pills in Example 1 were dissolved by the small intestinal fluid with pH = 6.8, and then copper sulfate pentahydrate was given; experimental group 2 was the solution after the coated pills in Example 2 were dissolved by the small intestinal fluid with pH = 6.8, and then copper sulfate pentahydrate was given; experimental group 3 was the solution after the coated pills in Example 3 were dissolved by the small intestinal fluid with pH = 6.8, and then copper sulfate pentahydrate was given. Control group 1 was the solution after the coated pills in comparative example 1 were dissolved by the small intestinal fluid with pH = 6.8, and then copper sulfate pentahydrate was given. The model group was a copper sulfate pentahydrate solution. The purpose of copper sulfate pentahydrate is to color neutrophils.

[0062] Among them, zebrafish were raised in fish farming water at 28°C (water quality: 200 mg of instant sea salt was added to every 1L of reverse osmosis water, the conductivity was 450-550 μS / cm; pH was 6.5-8.5; hardness was 50-100 mg / L CaCO3).

[0063] The positive control indomethacin concentration was 60.0 μM, and a normal control group and a model control group were set up at the same time, with a capacity of 3 mL per well. After treatment at 28°C for 1 hour, except for the normal control group, the other experimental groups were given water-soluble copper sulfate pentahydrate to establish a zebrafish inflammation model. After further treatment at 28°C for 2 hours, 10 zebrafish were randomly selected from each experimental group and photographed under a fluorescence microscope. The data were analyzed and collected using NIS-Elements D 3.20 advanced image processing software, and the number of neutrophils in the inflammatory site of zebrafish was analyzed. The statistical analysis results of this indicator were used to evaluate the anti-inflammatory efficacy of the sample. The statistical processing results are expressed as mean ± SE. SPSS26.0 software was used for statistical analysis, and p < 0.05 indicated that the difference was statistically significant. The test results are shown in Table 1.

[0064] Table 1 Evaluation of inflammation-relief efficacy-neutrophil test results (n=10)

[0065]

[0066]

[0067] Compared with the model control group, *p<0.05, ***p<0.001

[0068] From Table 1, it can be seen that the anti-inflammatory effects of experimental group 1, experimental group 2, experimental group 3 and comparison group 1 are worse than those of the model control group and the positive control group; at the same time, the anti-inflammatory effect of comparison group 1 is not as good as that of experimental group 1, experimental group 2 and experimental group 3. This is because carboxylic acid can improve the intestinal environment and alleviate intestinal problems caused by intestinal flora disorders and redox imbalance caused by various reasons; limonin can achieve better anti-inflammatory effects by reducing inflammation in the intestine after the environment is improved, that is, carboxylic acid and limonin have a synergistic effect in anti-inflammatory applications.

[0069] In summary, after the encapsulated drug in the present application enters the human body, its outer coating shell is decomposed, so that the internal effective ingredients are released, and the effective ingredients include a first exosome loaded with limonin and a second exosome loaded with hydroxy acid. The exosome contains cell-specific proteins, lipids and nucleic acids, which play a role in regulating cell status and function. At the same time, the exosome also contains rich biological factors, which can promote cell metabolism, activate cell regeneration ability, and repair damaged tissues; when the exosomes are gradually dissolved, the limonin and carboxyl acid encapsulated therein are released. Under the coordinated action of the exosome biological factors, the carboxyl acid can improve the intestinal environment and alleviate intestinal problems caused by various reasons such as intestinal flora disorders and redox imbalance; limonin is used to reduce inflammation in the intestine after the environment is improved; in the present application, the encapsulated drug can achieve targeted release, and on the basis of the improvement of the exosome biological factors and carboxyl acids, limonin can achieve effective anti-inflammatory effects on the intestine, and has a targeted and efficient anti-inflammatory effect.

[0070] It can be understood that the above embodiments only express the preferred implementation modes of the present invention, and the descriptions thereof are relatively specific and detailed, but they cannot be understood as limiting the patent scope of the present invention. It should be pointed out that, for ordinary technicians in this field, the above technical features can be freely combined without departing from the concept of the present invention, and several deformations and improvements can be made, which all belong to the protection scope of the present invention. Therefore, all equivalent changes and modifications made to the scope of the claims of the present invention should belong to the coverage of the claims of the present invention.

Claims

1. A coated drug loaded with limonin, characterized in that: include: The coating shell and the functional components located in the coating shell include a first exosome loaded with limonin and a second exosome loaded with hydroxy acid.

2. A coated drug loaded with limonin according to claim 1, characterized in that, The hydroxy acid comprises the following components in parts by weight: 35-45 parts of lactic acid, 30-40 parts of malic acid and 15-30 parts of citric acid.

3. A coated drug loaded with limonin according to claim 1, characterized in that, The drug-encapsulated coating shell is made of polyacrylic acid resin material.

4. A coated drug loaded with limonin according to claim 1, characterized in that, The coating shell of the coated drug is enteric-coated type I acrylic resin, and the dissolution pH of the coating shell is greater than 5.

5.

5. A coated drug loaded with limonin according to claim 1, characterized in that: The weight ratio of the first exosomes to the second exosomes is 70-80:20-30.

6. A method for preparing a coated drug loaded with limonin, characterized in that: include: loading limonin into exosomes to form first exosomes; loading hydroxy acids into exosomes to form second exosomes; The first exosomes and the second exosomes are prepared into coated drugs through coating technology.

7. The method for preparing a coated drug loaded with limonin according to claim 6, characterized in that: Limonin is encapsulated into exosomes to form the first exosomes by incubation, electroporation, extrusion, ultrasound or freeze-thaw method.

8. The method for preparing a coated drug loaded with limonin according to claim 6, characterized in that: Hydroxy acids are encapsulated into exosomes to form second exosomes by incubation, electroporation, extrusion, ultrasound or freeze-thaw method.

9. Use of a coated drug loaded with limonin according to any one of claims 1 to 5 in the field of treating enteritis.

Citation Information

Patent Citations

  • Multi-layer coating type essential oil organic acid compound feed additive and preparation method and application thereof

    CN110100965A

  • Enteric coated type feed acidifying agent and preparation method thereof

    CN110150471A

  • Method for producing limonin lipid nanoparticle enriched lemon juice

    CN111202193A

  • Analgesic agent

    JP1997286789A